Prolidase deficiency, a rare inborn error of immunity, clinical phenotypes, immunological features, and proposed treatments in twins

Allergy, Asthma & Clinical Immunology - 2022
Nora Alrumayyan1, Drew Slauenwhite1, Sarah M. McAlpine1, Susan A. Roberts1, Thomas B. Issekutz1, Adam M. Huber2, Zaiping Liu3, Beáta Dérfalvi1
1Division of Immunology, Department of Paediatrics, Dalhousie University, IWK Health Centre, Halifax, Canada
2Division of Rheumatology, Department of Paediatrics, Dalhousie University, IWK Health Centre, Halifax, Canada
3Division of Clinical Biochemistry & Maritime Newborn Screening, Department of Pathology and Laboratory Medicine, Dalhousie University, IWK Health Centre, Halifax, Canada

Tóm tắt

AbstractBackgroundProlidase deficiency (PD) is an autosomal recessive inborn multisystemic disease caused by mutations in thePEPDgene encoding the enzyme prolidase D, leading to defects in turnover of proline-containing proteins, such as collagen. PD is categorized as a metabolic disease, but also as an inborn error of immunity. PD presents with a range of findings including dysmorphic features, intellectual disabilities, recurrent infections, intractable skin ulceration, autoimmunity, and splenomegaly. Despite symptoms of immune dysregulation, only very limited immunologic assessments have been reported and standard therapies for PD have not been described. We report twin females with PD, including comprehensive immunologic profiles and treatment modalities used.Case presentationPatient 1 had recurrent infections in childhood. At age 13, she presented with telangiectasia, followed by painful, refractory skin ulcerations on her lower limbs, where skin biopsy excluded vasculitis. She had typical dysmorphic features of PD. Next-generation sequencing revealed pathogenic compound heterozygous mutations (premature stop codons) in thePEPDgene. Patient 2 had the same mutations, typical PD facial features, atopy, and telangiectasias, but no skin ulceration. Both patients had imidodipeptiduria. Lymphocyte subset analysis revealed low-normal frequency of Tregcells and decreased frequency of expression of the checkpoint molecule CTLA-4 in CD4+TEMcells. Analysis of Th1, Th2, and Th17 profiles revealed increased inflammatory IL-17+CD8+TEMcells in both patients and overexpression of the activation marker HLA-DR on CD4+TEMcells, reflecting a highly activated proinflammatory state. Neither PD patient had specific antibody deficiencies despite low CD4+CXCR5+Tfhcells and low class-switched memory B cells. Plasma IL-18 levels were exceptionally high.ConclusionsImmunologic abnormalities including skewed frequencies of activated inflammatory CD4+and CD8+TEMcells, decreased CTLA-4 expression, and defects in memory B cells may be a feature of immune dysregulation associated with PD; however, a larger sample size is required to validate these findings. The high IL-18 plasma levels suggest underlying autoinflammatory processes.

Từ khóa


Tài liệu tham khảo

Goodman SI, Solomons CC, Muschenheim F, McIntyre CA, Miles B, O’Brien D. A syndrome resembling lathyrism associated with iminodipeptiduria. Am J Med. 1968;45(1):152–9.

Spodenkiewicz M, Spodenkiewicz M, Cleary M, Massier M, Fitsialos G, Cottin V, et al. Clinical genetics of prolidase deficiency: an updated review. Biology (Basel). 2020;9(5):1–18.

Ferreira CR, Wang H. Prolidase deficiency. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Mirzaa GM, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; pp. 1993–2022.

Hershkovitz T, Hassoun G, Indelman M, Shlush LI, Bergman R, Pollack S, et al. A homozygous missense mutation in PEPD encoding peptidase D causes prolidase deficiency associated with hyper-IgE syndrome. Clin Exp Dermatol. 2006;31(3):435–40.

Falik-Zaccai TC, Khayat M, Luder A, Frenkel P, Magen D, Brik R, et al. A broad spectrum of developmental delay in a large cohort of prolidase deficiency patients demonstrates marked interfamilial and intrafamilial phenotypic variability. Am J Med Genet. 2010;153(1):46–56.

Rayment JH, Jobling R, Bowdin S, Cutz E, Dell SD. Prolidase deficiency diagnosed by whole exome sequencing in a child with pulmonary capillaritis. ERJ Open Res. 2019;5(2):00205–2018.

Bousfiha A, Jeddane L, Picard C, Al-Herz W, Ailal F, Chatila T, et al. human inborn errors of immunity: 2019 update of the IUIS phenotypical classification. J Clin Immunol. 2020;40(1):66–81.

Butbul Aviel Y, Mandel H, Avitan Hersh E, Bergman R, Adiv OE, Luder A, et al. Prolidase deficiency associated with systemic lupus erythematosus (SLE): single site experience and literature review. Pediatr Rheumatol. 2012;10(1):18.

Chasset F, Richez C, Martin T, Belot A, Korganow AS, Arnaud L. Rare diseases that mimic systemic lupus erythematosus (Lupus mimickers). Jt Bone Spine. 2019;86(2):165–71.

Sato S, Ohnishi T, Uejima Y, Furuichi M, Fujinaga S, Imai K, et al. Induction therapy with rituximab for lupus nephritis due to prolidase deficiency. Rheumatology. 2020;59(10):e57–9.

Kurien BT, D’Sousa A, Bruner BF, Gross T, James JA, Targoff IN, et al. Prolidase deficiency breaks tolerance to lupus-associated antigens. Int J Rheum Dis. 2013;16(6):674–80.

Costa-Reis P, Sullivan KE. Monogenic lupus: it’s all new! Curr Opin Immunol. 2017;49:87–95.

Dunn R, Varigos G, Winship I. A photographic essay of prolidase deficiency. Clin Dysmorphol. 2011;20(4):194–9.

Kurien BT, D’Sousa A, Bruner BF, Gross T, James JA, Targoff IN, et al. Prolidase deficiency breaks tolerance to lupus-associated antigens. Int J Rheum Dis. 2013;16(6):678.

Lupi A, Rossi A, Campari E, Pecora F, Lund AM, Elcioglu NH, et al. Molecular characterisation of six patients with prolidase deficiency: identification of the first small duplication in the prolidase gene and of a mutation generating symptomatic and asymptomatic outcomes within the same family. J Med Genet. 2006;43(12):1–7.

Hui K -S, Lajtha A. Activation and inhibition of cerebral prolidase. J Neurochem. 1980;35(2):489–94.

Solak B, Kara RO, Erdem T, Muftuoglu T. A case of prolidase deficiency accompanying leg ulcers. Int J Low Extrem Wounds. 2015;14(1):92–4.

Freij BJ, Der Kaloustian VM. Prolidase deficiency: a metabolic disorder presenting with dermatologic signs. Int J Dermatol. 1986;25(7):431–3.

Wilk P, Uehlein M, Piwowarczyk R, Dobbek H, Mueller U, Weiss MS. Structural basis for prolidase deficiency disease mechanisms. FEBS J. 2018;285(18):3422–41.

Besio R, Maruelli S, Gioia R, Villa I, Grabowski P, Gallagher O, et al. Lack of prolidase causes a bone phenotype both in human and in mouse. Bone. 2015;72:53–64. https://doi.org/10.1016/j.bone.2014.11.009.

Kikuchi S, Tanoue A, Endo F, Wakasugi S, Matsuo N, Tsujimoto G. A novel nonsense mutation of the PEPD gene in a Japanese patient with prolidase deficiency. J Hum Genet. 2000;45(2):102–4.

Ferreira CR, Cusmano-Ozog K. Spurious elevation of multiple urine amino acids by ion-exchange chromatography in patients with prolidase deficiency. In: Morava E, Baumgartner M, Patterson M, Rahman S, Zschocke J, Peters V, editors. JIMD Reports, Volume 31. Berlin, Heidelberg: Springer; 2017. p. 45–9.

Pandit RA, Chen CJ, Butt TA, Islam N. Identification and analysis of a novel mutation in PEPD gene in two Kashmiri siblings with prolidase enzyme deficiency. Gene. 2013;516(2):316–9. https://doi.org/10.1016/j.gene.2012.12.070.

Slauenwhite D, McAlpine SM, Hanly JG, Malik A, Haidl ID, Marshall JS, et al. Association of a Type 2–Polarized T Cell Phenotype with methotrexate nonresponse in patients with rheumatoid arthritis. Arthritis Rheumatol. 2020;72(7):1091–102.

Shrinath M, Walter JH, Haeney M, Couriel JM, Lewis MA, Herrick AL. Prolidase deficiency and systemic lupus erythematosus. Arch Dis Child. 1997;76(5):441–4.

Cleary MA, Heaney M, Couriel JM, Walter JH. Immune function in prolidase deficiency. J Inherit Metab Dis. 1994;17(3):345–8.

Lubick KJ, Robertson SJ, McNally KL, Freedman BA, Rasmussen AL, Taylor RT, et al. Flavivirus antagonism of type i interferon signaling reveals prolidase as a regulator of IFNAR1 surface expression. Cell Host Microbe. 2015;18(1):61–74. https://doi.org/10.1016/j.chom.2015.06.007.

Ma CS, Deenick EK, Batten M, Tangye SG. The origins, function, and regulation of T follicular helper cells. J Exp Med. 2012;209(7):1241–53.

Lopes I, Marques L, Neves E, Silva A, Taveira M, Pena R, et al. Prolidase deficiency with hyperimmunoglobulin E: a case report. Pediatr Allergy Immunol. 2002;13(2):140–2.

Cleary MA, Heaney M, Couriel JM, Walter JH, Alehashemi S, Goldbach-Mansky R, et al. A homozygous missense mutation in PEPD encoding peptidase D causes prolidase deficiency associated with hyper-IgE syndrome. Clin Exp Dermatol. 2012;72(3):1091–102.

Ma CS, Deenick EK. The circulating life of a memory T-follicular helper cell. Clin Transl Immunol. 2017;6(5):e141.

Ahsan Rizvi S, Elder M, Beasley G. A novel manifestation of prolidase deficiency in a toddler diagnosed with very-early-onset crohn disease. J Pediatr Gastroenterol Nutr. 2019;69(3):e89-90.

Klar A, Navon-Elkan P, Rubinow A, Branski D, Hurvitz H, Christensen E, et al. Prolidase deficiency: It looks like systemic lupus erythematosus but it is not. Eur J Pediatr. 2010;169(6):727–32.

Mohr A, Atif M, Balderas R, Gorochov G, Miyara M. The role of FOXP3+ regulatory T cells in human autoimmune and inflammatory diseases. Clin Exp Immunol. 2019;197(1):24–35.

McKinney EF, Lee JC, Jayne DRW, Lyons PA, Smith KGC. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature. 2015;523(7562):612–6.

Källström E, Roscher I, Andreasson A, Bäck O, Källström E, Roscher I, et al. Decreased frequency of intracellular IFN- g producing T cells in whole blood preparations from patients with atopic dermatitis. Exp Dermatol. 2002;11(6):556–63.

Alehashemi S, Goldbach-Mansky R. Human autoinflammatory diseases mediated by NLRP3-, Pyrin-, NLRP1-, and NLRC4-inflammasome dysregulation updates on diagnosis, treatment, and the respective roles of IL-1 and IL-18. Front Immunol. 2020;11:1840.

Misiura M, Miltyk W. Current understanding of the emerging role of prolidase in cellular metabolism. Int J Mol Sci. 2020;21(16):1–20.

Surazynski A, Miltyk W, Palka J, Phang JM. Prolidase-dependent regulation of collagen biosynthesis. Amino Acids. 2008;35(4):731–8.

Mitchell S, Vargas J, Hoffmann A. Signaling via the NFκB system. Wiley Interdiscip Rev Syst Biol Med. 2016;8(3):227–41.

Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45(11):1274–85.

Insolia V, Priori EC, Gasperini C, Coppa F, Cocchia M, Iervasi E, et al. Prolidase enzyme is required for extracellular matrix integrity and impacts on postnatal cerebellar cortex development. J Comp Neurol. 2020;528(1):61–80.

Royce PM, Danks DM. Normal hydroxylation of proline in collagen synthesized by skin fibroblasts from a patient with prolidase deficiency. J Inherit Metab Dis. 1982;5(2):111–3.

lsazade A, Elçin G, Doğan S, Gülseren D, Gököz Ö, Gürbüz B, et al. A rare cause of cutaneous ulceration: Prolidase deficiency. Int Wound J. 2019;16(4):1057–8.

Dunn R, Dolianitis C. Prolidase deficiency: the use of topical proline for treatment of leg ulcers. Australas J Dermatol. 2008;49(4):237–8.

Monafo V, Marseglia GL, Maghnie M, Dyne KM, Cetta G. Transient beneficial effect of GH replacement therapy and topical GH application on skin ulcers in a boy with prolidase deficiency. Pediatr Dermatol. 2000;17(3):227–30.

Karthikeyan K, Polly D, Asmathulla S, Balamurugan R, Kaviraj M. Topical proline therapy in prolidase deficiency. Clin Exp Dermatol. 2019;44(3):344–6.

Good AJ, Nielson CB, Schoch JJ. Topical tacrolimus therapy in the management of lower extremity ulcers due to prolidase deficiency. Pediatr Dermatol. 2019;36(6):926–8.

Süßmuth K, Metze D, Muresan AM, Lehmberg K, Zur Stadt U, Speckmann C, et al. Ulceration in prolidase deficiency: successful treatment with anticoagulants. Acta Derm Venereol. 2020;100(1):10–1.

Olasz L, Nyárády Z. The role of platysma-based flaps in the reconstruction of massive through and through facial defects. J Plast Reconstr Aesthetic Surg. 2008;61(10):1254–6.

Beradesca E, Fideli D, Bellosta M, Dyne KM, Zanaboni G, Cetta G. Blood transfusions in the therapy of a case of prolidase deficiency. Br J Dermatol. 1992;126(2):193–5.

Bakhtiar S, Fekadu J, Seidel MG, Gambinieri E. Allogeneic hematopoietic stem cell transplantation for congenital immune dysregulatory disorders. Front Pediatr. 2019;7:461.

Thông tin
Thông tin xuất bản

Allergy, Asthma & Clinical Immunology

Thông tin tác giả